ArticleBJC reports2025
Patient derived cancer-associated fibroblasts from non-small cell lung cancer undergo phenotypic drift in culture.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors.Science advances · 2026Article
- Functional consistency and molecular evolution: a comprehensive characterization of primary endometrial cancer-associated fibroblasts during in vitro expansion.Journal of translational medicine · 2026Article
- Adaptive plasticity of aspartate metabolism in succinate dehydrogenase-deficient cancer cells.bioRxiv : the preprint server for biology · 2026Article
- Modeling CAF-tumor interactions to overcome therapy resistance.Journal of experimental & clinical cancer research : CR · 2026Review
- The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer-associated fibroblasts (CAFs) are the predominant cell type in the stroma of many solid organ malignancies, including non-small cell lung cancer (NSCLC). They exhibit considerable phenotypic and functional heterogeneity and are widely used in functional assays and co-culture models. CAF research frequently involves the in vitro expansion and maintenance of CAFs to facilitate functional assays and co-culture studies. However, less is known about how in vitro culture temporally affects CAF phenotype.
methodsWe characterised the phenotype of CAFs from NSCLC patients compared to non-cancerous lung fibroblasts using conventional in vitro conditions by tracking changes in CAF subset marker expression levels by flow cytometry. Additional transcriptomic and functional analyses were performed to determine differences between CAFs and non-cancerous fibroblasts.
resultsWe demonstrate that CAFs from NSCLC undergo phenotypic drift in culture, and that there is a convergence to a subset phenotype predominantly upregulated in non-cancerous lung. Additionally, we demonstrate the phenotype, transcriptome and function of fibroblasts converge between CAFs and fibroblasts from non-cancerous lung by the third culture passage, suggesting that in vitro conditions promote this phenotype.
conclusionWe highlight the need to understand and monitor the culture phenotype during functional studies with CAFs, as the heterogeneity found in the tumour microenvironment is rapidly lost in cultured cells.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.